NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- May marks Women’s Health Month, a timely reminder that while many women prioritize the health of others, their own well-being matters just as much. Recently, Dr. Yesmean Wahdan, Board-Certified OB/GYN and Medical Affairs Head for Women’s Health at Bayer, participated in a nationwide satellite media tour to share important advice for women of all ages. Women experience unique and evolving health milestones, and being proactive with annual checkups, including OB/GYN ...

拜耳 近日 宣布与 成都凌泰氪生物技术有限公司 （ IncTAC ，以下简称"凌泰氪生物"） 、 杭州腾砥生物 医药科技有限公司 （ 20n Bio ，以下简称"腾砥生物"） 签署协议，这两家生物技术企业将入驻 拜耳 Co.Lab 共创平台 ，借助拜耳全球创新和合作网络以及深厚的行业经验，对接全球医药产业资源，加速全 新技术平台的创新突破。 凌泰氪生物创始人、董事长 宋旭 教授表示： " 加入拜耳 Co.Lab 表明了凌泰氪针对具有未满足临床需求的 疾病开发出创新性治疗方法的承诺 。我们认可并赞赏拜耳基于其在医药领域专业、开放的协同创新生态体 系对初创企业发展的支持。 相信通过这一战略合作，凌泰氪将加速递送平台的 '领跑'，为全球患者带来突 破性疗法。 " 凌泰氪生物签约入驻拜耳Co.Lab 凌泰氪生物通过探索 长非编码 RNA （ lncRNA ） ，致力于为临床上一系列未满足的疾病治疗需求提供解 决方案。凌泰氪生物开创了基于 lncRNA 等天然分子实现药物肝外靶向递送的平台技术，已开发出肿瘤、 腾砥生物与凌泰氪生物签约入驻拜耳 Co.Lab ，依托拜耳全球开放创新网络，加速前沿创新技术进程 腾砥生物能够 ...

Core Insights - Bayer A.G.'s stock price is currently trading near multi-year lows, indicating potential undervaluation in the market [1] Financial Performance - The company has recently published its earnings results, which are critical for assessing its financial health and future prospects [1]

Core Viewpoint - Bayer is preparing a plan to reach a settlement regarding the large-scale lawsuits related to the carcinogenicity of its herbicide "Roundup" in Missouri, and if the settlement fails, the company may consider filing for bankruptcy for its subsidiary Monsanto [1] Group 1 - Bayer has already paid approximately $10 billion to resolve disputes concerning the carcinogenic claims associated with "Roundup" [1]

拜耳股价在法兰克福市场下跌7%。 ...

Core Insights - Bayer AG reported a net profit of 1.3 billion euros (approximately $1.45 billion) for Q1 2025, a decrease from 2 billion euros in the same period last year [1] - The company confirmed its outlook for the full year 2025 at constant currencies despite current tariff announcements and mitigation measures [1] - Bayer is reorganizing its Crop Science division in Germany to enhance competitiveness globally [1][2] Financial Performance - Adjusted earnings were 65 cents, surpassing the consensus estimate of 38 cents [5] - Sales reached $14.45 billion (13.74 billion euros), exceeding the consensus of $13.39 billion [5] - EBITDA before restructuring and litigation charges fell 7% year-on-year to 4 billion euros in Q1 [5] - Sales in the agricultural business decreased by 3.3% to 7.58 billion euros [5] - Sales of prescription medicines increased by 4.1% to 4.548 billion euros [5] - Significant growth rates were recorded for new products, including a 77.5% increase for the cancer drug Nubeqa (515 million euros) and an 86.6% increase for Kerendia (161 million euros) [5] Strategic Changes - Bayer will focus on advanced, strategic products that provide clear benefits to farmers and are difficult for generic manufacturers to replicate [2] - The company plans to cease operations in Frankfurt by late 2028 as part of its restructuring efforts [2][3] - The Dormagen site will remain Bayer's main production hub for crop protection products, but it will be streamlined to maintain competitiveness [3] - Bayer will stop producing generic active ingredients and formulations that are widely available at lower prices globally [3] - The changes are expected to affect approximately 200 of the 1,200 employees at the Dormagen site, primarily in active ingredient production and formulation [3]

拜耳首席执行官：（关于关税问题）我们目前没有立即计划重新审视我们全球平衡的制造布局。 ...

拜耳股价上涨6.1%，该公司第一季度业绩超出预期。 ...

拜耳第一季度 净利润为12.99亿欧元。 ...

拜耳第一季度调整后息税折旧及摊销前利润40.9亿欧元，预估38.8亿欧元。 第一季度销售额137.4亿欧元，预估135.2亿欧元。 第一季度经调整EBITDA利润率29.7％，预估28.5％。 第一季度负自由现金流15.3亿欧元，预估负25.3亿欧元。 第一季度核心每股收益2.49欧元，预估2.34欧元。 第一季度期末负债净额342.6亿欧元，预估347.9亿欧元。 ...